Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06393374
Status:
RECRUITING
Last Update Posted:
2024-07-11
First Post:
2024-04-26
Brief Title:
Sacituzumab Tirumotecan MK-2870 Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR MK-2870-012
Sponsor:
Organization:
Merck Sharp Dohme LLC